Status:
COMPLETED
Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions
Lead Sponsor:
Kamuzu University of Health Sciences
Conditions:
Status Epilepticus
Convulsions
Eligibility:
All Genders
2-12 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emerg...
Detailed Description
The ideal first line anticonvulsant agent would be one that can be safely and easily given at a primary health care facility. It should be quick acting, have minimal cardiorespiratory side effects and...
Eligibility Criteria
Inclusion
- Children aged between 2 months and 12 years
- Presenting with generalised convulsions
Exclusion
- Any child who had received an anticonvulsant agent within 1 hour of presentation
- Seizure stopped with rapid cooling or treatment of hypoglycaemia
- Features consistent with organophosphate poisoning, hepatic or hypertensive encephalopathy
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00116064
Start Date
July 1 2004
End Date
June 1 2005
Last Update
July 21 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Paediatric Emergency Department, Queen Elizabeth Central Hospital
Blantyre, Malawi